Rare diseases
Investigational molecules
Locations
Ul. Gesia 3, 22-400 Zamosc, Poland
Pro Life Medica Sp. z o.o. in Zamosc, Poland specialises in clinical trials of conditions such as Crohn's disease, Colitis ulcerative, Arteriosclerosis, Hypertriglyceridaemia, and other specialisations. This site conducts important research.
At Pro Life Medica Sp. z o.o. the ETG Zamość department focuses on Cardiovascular Diseases and related lipid disorders, evaluating new treatments to lower triglyceride levels and mitigate atherosclerotic risk.
The site’s investigators are collaborating to advance therapeutic options for heart and vascular health.
Research at the Zamość clinic includes innovative work on Crohn's Disease, aiming to improve endoscopic response through oral medication strategies.
These studies support the development of more effective therapies for inflammatory bowel conditions.
The facility also addresses metabolic lipid abnormalities, such as Hypertriglyceridemia, exploring how targeted interventions can improve overall metabolic health.
With a focused team of 19 investigators, the site contributes valuable data to the field of metabolic disease research.
Clinical trials currently enrolling participants at this site.
Study of RO7790121 (afimkibart) for Treatment and Long-term Management in Adults with Moderate to Severe Crohn's Disease
PolandStudy on the Effectiveness and Safety of Obefazimod for Patients with Moderate to Severe Crohn's Disease After Inadequate Response to Other Treatments
PolandStudy on Eltrekibart and Mirikizumab for Adults with Moderate to Severe Ulcerative Colitis
PolandStudy on the Effects of Zasocitinib for Patients with Moderate to Severe Crohn's Disease
PolandStudy comparing MB04 (etanercept biosimilar) with Enbrel in patients with moderate to severe rheumatoid arthritis who are taking methotrexate
PolandStudy of ISIS 678354 for Patients with Severe High Triglycerides
PolandStudy on the Effectiveness and Safety of Efgartigimod for Adults with Primary Sjögren's Syndrome
PolandStudy on BI 3032950 for Patients with Moderate to Severe Ulcerative Colitis
PolandStudy on the Effectiveness and Safety of Guselkumab and Ustekinumab for Patients with Moderate to Severe Crohn's Disease
PolandStudy Comparing AVT16 and Vedolizumab for Adults with Moderate to Severe Ulcerative Colitis
PolandStudy on the Long-Term Effects of TEV-48574 (Duvakitug) for Adults with Moderate to Severe Ulcerative Colitis or Crohn's Disease
PolandStudy of Oral Ozanimod as Maintenance Treatment for Adults with Moderate to Severe Crohn's Disease
PolandMove up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.
See the offer for sitesTell us about your condition – we search every trial in Europe and connect you with the right site.
